Abstract
Purpose: To report on the rapid and sustained effect following injection of intravitreal methotrexate (IVTMTX) in intraocular T-cell lymphoma.Design: Report of 2 cases.Methods: A young male with natural killer/T-cell lymphoma presented with infiltrative nodular iridocyclitis and received a single IVTMTX. An elderly female with peripheral T-cell lymphoma presented with a hypopyon, infiltrative iridocyclitis, and choroidal effusions and received 3 IVTMTX over 4 months.Results: Both patients responded well after the first injection, with resolution of signs within 1 week and improvement in vision.Conclusions: IVTMTX may be effective as a palliative, vision-restoring measure in patients with systemic T-cell lymphoma.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
